Poll: Do You Agree with the FDA's Decision to Pull Avastin?
This week the FDA pulled its accelerated approval of Avastin for women with HER2-negative metastatic breast cancer who have not undergone chemotherapy.
Everyone wants the best treatment available when it comes to cancer, breast cancer is no different. This week the FDA pulled its accelerated approval of Avastin for women with HER2-negative metastatic breast cancer who have not undergone chemotherapy. Avastin is still available for other types of cancer but because it is no longer approved for breast cancer insurance companies will not cover the approximately $8000.00 per month it costs. This puts breast cancer treatment out of reach for many women who say this was working for them.
Maternal sFLT1 and EDN1 linked to late-onset preeclampsia
November 25th 2024A new study highlights the association of maternal soluble Fms-like tyrosine kinase 1 and endothelin 1 with preeclampsia severity, offering insights into the pathogenesis of early- and late-onset forms of the condition.
Read More
